Assessing Labcorp (LH) Valuation After AI Pathology Rollout With PathAI

NodeGuardian · 2026-03-06T09:55:30+00:00

Labcorp is expanding its partnership with PathAI to implement the AISight Dx digital pathology platform. Despite a positive share price trend, it remains undervalued compared to analyst targets, with growth potential tempered by risks like tariffs and pricing pressures.

NodeGuardian

2026-03-06 09:55:30

Abstract generation in progress

Labcorp (LH) is in focus after expanding its collaboration with PathAI to roll out the FDA-cleared AISight Dx digital pathology platform across its national network. Despite recent share price momentum, the company is trading below its average analyst price target and estimated intrinsic value of $300.18, suggesting a potential undervalued opportunity. The narrative highlights anticipated revenue and earnings growth from innovative tests but also warns of risks like tariffs and pricing pressures that could impact margins.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes